Peptide Types: A Complete Classification Guide

Walk into any peptide clinic and you’ll hear dozens of names — BPC-157, semaglutide, CJC-1295, GHK-Cu — thrown around as if everyone already knows what category each belongs to. Most people don’t. And the confusion is understandable: peptides are used for everything from fat loss to wound healing to hair regrowth. Without a framework for how they’re organized, it’s hard to make sense of which ones do what. If you’re looking at peptides for muscle growth or any other goal, understanding the underlying categories makes every other conversation easier.

This guide classifies therapeutic peptides into clear functional groups. We’re focusing on the peptides actually used in clinical practice and research — not the 7,000+ peptides cataloged in databases for academic purposes. For a broader reference, see our complete list of peptides. And if you’re new to the concept entirely, our peptide therapy overview covers the fundamentals.

Key Takeaways

• Therapeutic peptides fall into 7 major functional categories based on what they do in the body
• Growth hormone peptides are the largest class in clinical use, split into GHRH analogs and secretagogues
• Each category has distinct mechanisms, dosing approaches, and safety profiles
• Many peptides cross categories — BPC-157 affects both healing and gut function, for example

Table of Contents

• How Peptides Are Classified
• Type 1: Growth Hormone Peptides
• Type 2: Weight Management Peptides
• Type 3: Healing and Recovery Peptides
• Type 4: Cosmetic and Anti-Aging Peptides
• Type 5: Immune and Antimicrobial Peptides
• Type 6: Neuropeptides
• Type 7: Signaling and Regulatory Peptides
• How to Choose the Right Peptide Type
• Side Effects and Safety
• FAQ
• Sources

How Peptides Are Classified

Peptides are short chains of amino acids — typically 2 to 50 amino acids long. Anything longer is generally classified as a protein. But “peptide” is a structural description, not a functional one. Saying something is a peptide tells you about its size, not what it does.

In scientific literature, peptides are classified multiple ways:

By structure: Linear, cyclic, or branched. Alpha-helical, beta-sheet, or extended. This matters for stability and how the peptide interacts with receptors [1].

By origin: Endogenous (made by your body, like ghrelin or oxytocin), synthetic (lab-created analogs like sermorelin), or naturally derived (from food sources, venom, or microbial products) [2].

By function: This is the most useful classification for patients and clinicians. What does the peptide actually do? That’s how we’ll organize this guide.

A 2025 systematic review in Computers in Biology and Medicine proposed four broad categories: regulatory/signaling, therapeutic/medicinal, sensory/nutritional, and structural/functional [3]. We’ll use a more granular clinical framework below.

Type 1: Growth Hormone Peptides

This is the largest category in peptide therapy clinics. These peptides increase growth hormone (GH) output through two distinct mechanisms.

GHRH Analogs

Growth hormone releasing hormone analogs mimic your body’s natural GHRH signal from the hypothalamus. They tell the pituitary gland to release GH through the same pathway your brain uses.

Key peptides:

• Sermorelin — synthetic version of the first 29 amino acids of GHRH. Was FDA-approved for pediatric GH deficiency before commercial discontinuation [4].
• CJC-1295 — modified GHRH analog with a longer half-life (days vs minutes for native GHRH). Often combined with ipamorelin. See our CJC-1295 + Ipamorelin guide for the full breakdown.
• Tesamorelin — FDA-approved GHRH analog for HIV-associated lipodystrophy. Reduces visceral fat and improves body composition [5].

GH Secretagogues (Ghrelin Mimetics)

These bind to the ghrelin receptor (GHS-R1a) on the pituitary, triggering GH release through a different pathway than GHRH. Think of it as a second key to the same lock — but from a different angle.

Key peptides:

• Ipamorelin — the most selective GH secretagogue available. Increases GH without significantly raising cortisol or prolactin [6]. Widely prescribed for body composition, recovery, and sleep.
• GHRP-2 — potent but less selective than ipamorelin. Increases appetite and cortisol more significantly.
• GHRP-6 — strong GH release but notable hunger stimulation. Less commonly used now that ipamorelin is available.
• Hexarelin — most potent GHRP, but raises cortisol and prolactin. Limited clinical use due to side effects.
• MK-677 (Ibutamoren) — oral GH secretagogue (technically not a peptide, but targets the same receptor). Convenient but raises blood glucose over time [7].

Why This Matters

GHRH analogs and secretagogues work through complementary mechanisms. That’s why CJC-1295 + Ipamorelin is one of the most popular stacks — you’re stimulating GH release from both pathways simultaneously.

Type 2: Weight Management Peptides

The GLP-1 receptor agonists have dominated headlines. They mimic glucagon-like peptide-1, a gut hormone that regulates appetite, insulin secretion, and gastric emptying.

Key peptides:

• Semaglutide (Ozempic, Wegovy) — once-weekly injection, 15-17% average weight loss in clinical trials [8]. FDA-approved for both diabetes and obesity.
• Tirzepatide (Mounjaro, Zepbound) — dual GIP/GLP-1 agonist. Up to 22.5% weight loss in trials [9]. The dual mechanism appears to offer advantages over GLP-1-only drugs.
• Liraglutide (Saxenda) — daily injection, older GLP-1 agonist. About 8% average weight loss.

These are the only peptide class with large-scale Phase III clinical trials and robust FDA approval for their primary indication. For a deeper comparison, read our guide on peptides for weight loss.

Other weight-related peptides:

• AOD 9604 — a fragment of human growth hormone (amino acids 176-191) studied for fat metabolism. Limited published human data.
• 5-Amino-1MQ — not a peptide per se, but often grouped with peptide therapies. Inhibits NNMT enzyme to support fat metabolism.

Type 3: Healing and Recovery Peptides

These peptides accelerate tissue repair — tendons, ligaments, muscles, gut lining, and more. They work through growth factor signaling, angiogenesis (new blood vessel formation), and inflammation modulation.

Key peptides:

• BPC-157 — Body Protection Compound, derived from a protein in gastric juice. Studied extensively in animal models for tendon repair, gut healing, muscle injury recovery, and even nerve regeneration [10]. Probably the most broadly researched healing peptide. No completed human clinical trials yet, which is its biggest limitation.
• TB-500 (Thymosin Beta-4) — promotes cell migration, blood vessel growth, and tissue repair. Used widely in equine medicine. Human data is mostly from cardiac repair studies [11].
• Pentadecapeptide BPC-157 + TB-500 stack — commonly used together for injury recovery, targeting overlapping but distinct repair pathways.

The healing peptide category overlaps with growth hormone peptides — GH itself is a powerful tissue repair signal, which is why CJC-1295/Ipamorelin is sometimes prescribed alongside BPC-157 for injury recovery.

Type 4: Cosmetic and Anti-Aging Peptides

These target skin quality, hair growth, pigmentation, and visible signs of aging through various mechanisms.

Key peptides:

• GHK-Cu — copper peptide that stimulates collagen synthesis, promotes wound healing, and has antioxidant activity. Naturally occurring in human plasma, with levels declining from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 [12]. Used topically and via injection.
• Epitalon (Epithalon) — activates telomerase, the enzyme that maintains chromosome telomere length. Animal studies show lifespan extension and melatonin production restoration [13]. Human data is limited to small studies.
• PT-141 (Bremelanotide) — melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in women. Acts on the central nervous system rather than vascular pathways [14].
• Melanotan II — stimulates melanin production for skin tanning. Also affects appetite and sexual function. Significant safety concerns including nausea, blood pressure changes, and potential mole changes. Not FDA-approved.

Topical peptides in skincare:

• Matrixyl (Palmitoyl Pentapeptide-4) — stimulates collagen and fibronectin production
• Argireline (Acetyl Hexapeptide-3) — inhibits neurotransmitter release at the neuromuscular junction, reducing fine lines
• Copper peptides (GHK-Cu) — available in both injectable and topical formulations

Type 5: Immune and Antimicrobial Peptides

Your immune system produces peptides as part of its defense toolkit. Therapeutic versions aim to modulate immune function or fight infections directly.

Key peptides:

• Thymosin Alpha-1 (Ta1) — produced by the thymus gland, enhances T-cell function and dendritic cell maturation. FDA-approved in over 30 countries (not the US) for hepatitis B and as an immune adjuvant [15]. Used off-label for chronic infections and immune deficiency.
• LL-37 — a human cathelicidin antimicrobial peptide that kills bacteria, viruses, and fungi by disrupting their membranes. Also modulates inflammatory responses [16].
• Defensins — a family of small cationic peptides (alpha and beta subtypes) that form part of innate immunity. Research focus, not yet in clinical peptide therapy.

Antimicrobial peptides (AMPs) represent one of the most active areas of pharmaceutical research. With antibiotic resistance growing, AMPs offer alternative mechanisms that bacteria find harder to develop resistance against. Over 3,000 natural AMPs have been identified [1].

Type 6: Neuropeptides

Neuropeptides are signaling molecules used by neurons to communicate. Several have therapeutic applications.

Key peptides:

• DSIP (Delta Sleep-Inducing Peptide) — nonapeptide isolated from brain tissue, studied for sleep promotion and stress modulation. Mixed clinical results but ongoing interest [17].
• Selank — synthetic analog of the naturally occurring tuftsin peptide. Anxiolytic (anti-anxiety) effects demonstrated in Russian clinical studies. Approved in Russia as an anxiolytic [18].
• Semax — synthetic ACTH analog that promotes BDNF (brain-derived neurotrophic factor) expression. Used in Russia for cognitive enhancement and stroke recovery [19].
• Dihexa — angiotensin IV analog studied for cognitive enhancement, particularly in Alzheimer’s disease models. Animal data only. Extremely potent at picomolar concentrations [20].

Neuropeptides carry additional considerations because they cross or interact with the blood-brain barrier. Dosing precision matters more, and the margin between therapeutic and excessive is often narrower.

Type 7: Signaling and Regulatory Peptides

This catch-all category includes peptides that modulate specific physiological pathways without fitting neatly into the above groups.

Key peptides:

• Kisspeptin — regulates the hypothalamic-pituitary-gonadal axis. Controls GnRH release, which drives testosterone and estrogen production. Studied for fertility applications [21].
• MOTS-c — mitochondrial-derived peptide that improves insulin sensitivity and metabolic function. Activated by exercise. Early-stage research showing promise for metabolic syndrome [22].
• Humanin — another mitochondrial peptide with neuroprotective and anti-apoptotic properties. Studied in Alzheimer’s and cardiovascular disease contexts [23].
• Oxytocin — the “bonding hormone.” Already used clinically for labor induction. Research into nasal oxytocin for social anxiety and autism spectrum conditions is ongoing.

How to Choose the Right Peptide Type

Matching the right peptide to your goal starts with identifying the category:

Goal	Primary Peptide Type	Common Starting Points
Muscle growth & recovery	GH peptides	CJC-1295 + Ipamorelin
Fat loss	Weight management	Semaglutide, Tirzepatide
Injury healing	Healing peptides	BPC-157, TB-500
Skin & hair	Cosmetic peptides	GHK-Cu, topical peptides
Sleep quality	GH peptides / Neuropeptides	CJC-1295 + Ipamorelin, DSIP
Immune support	Immune peptides	Thymosin Alpha-1

Most patients don’t need peptides from every category. A focused approach — one or two peptides targeting your primary concern — is better than a shotgun protocol. Your provider can help determine which type makes sense based on labs, symptoms, and goals.

Side Effects and Safety

Side effects are category-specific:

GH peptides: Water retention, tingling, joint stiffness, injection site reactions. Long-term IGF-1 elevation requires monitoring.

GLP-1 agonists: Nausea (most common, especially early), constipation or diarrhea, reduced appetite (intended), rare pancreatitis reports.

Healing peptides (BPC-157, TB-500): Generally well-tolerated. Limited human safety data is the main concern. Theoretical questions about effects on cancer biology remain unanswered.

Cosmetic peptides: Varies widely. GHK-Cu is well-tolerated. Melanotan II carries more significant risks (blood pressure, mole changes).

Neuropeptides: Higher caution warranted due to CNS activity. Dosing precision is more important. Limited long-term human data for most compounds.

General rules:

• Work with a prescribing clinician who monitors labs
• Start at lower doses and titrate up
• Report unexpected symptoms promptly
• Don’t source research chemicals when pharmaceutical-grade options exist

FAQ

What are the main types of peptides used in therapy?▼

The seven functional categories are: growth hormone peptides, weight management peptides (GLP-1 agonists), healing and recovery peptides, cosmetic and anti-aging peptides, immune and antimicrobial peptides, neuropeptides, and signaling/regulatory peptides. Growth hormone peptides and GLP-1 agonists are currently the most widely prescribed.

What is the difference between GHRH analogs and GH secretagogues?▼

GHRH analogs (like sermorelin and CJC-1295) mimic your body’s natural growth hormone releasing hormone, working through the GHRH receptor. GH secretagogues (like ipamorelin) bind to the ghrelin receptor instead. Both increase GH output, but through different pathways — which is why they’re often combined.

Are all peptides injectable?▼

No. GLP-1 agonists like semaglutide now have oral formulations. MK-677 is taken orally. Many cosmetic peptides (GHK-Cu, Matrixyl) are applied topically. BPC-157 has been studied both as an injection and oral capsule. That said, most therapeutic peptides in clinical practice are administered via subcutaneous injection because peptides are generally broken down in the digestive tract.

Which peptide type is best for beginners?▼

GH secretagogues like ipamorelin are often a good starting point — they’re well-studied, selective, and well-tolerated. For non-injectable options, topical copper peptides offer skin benefits without needles. The “best” type depends entirely on your goals, which a provider can help clarify during a peptide therapy consultation.

How many different peptides exist?▼

Over 7,000 naturally occurring peptides have been identified in the human body and other organisms. The Antimicrobial Peptide Database alone catalogs more than 3,000 entries [1]. But only a few dozen are commonly used in clinical peptide therapy. The rest are primarily of academic and pharmaceutical research interest.

Sources

1. Wang G, et al. “Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields.” Front Microbiol. 2020;11:582779. PMC: 7596191

2. Muttenthaler M, et al. “Trends in peptide drug discovery.” Nat Rev Drug Discov. 2021;20(4):309-325.

3. Arif M, et al. “Peptide classification field: An in-depth systematic literature review on peptide types, databases, datasets, predictors architectures and performance.” Comput Biol Med. 2025;186:109614.

4. Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging. 2006;1(4):307-8.

5. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359-70.

6. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-61.

7. Nass R, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-11.

8. Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity.” N Engl J Med. 2021;384(11):989-1002.

9. Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity.” N Engl J Med. 2022;387(3):205-216.

10. Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Curr Neuropharmacol. 2016;14(8):857-65.

11. Crockford D, et al. “Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications.” Ann N Y Acad Sci. 2010;1194:179-89.

12. Pickart L, et al. “GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes.” Cosmetics. 2015;2(3):236-47.

13. Khavinson VK, et al. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bull Exp Biol Med. 2003;135(6):590-2.

14. Kingsberg SA, et al. “Bremelanotide for the treatment of hypoactive sexual desire disorder.” Obstet Gynecol. 2019;134(5):899-908.

15. Tuthill C, et al. “Thymalfasin: biological properties and clinical applications.” Int Immunopharmacol. 2020;85:106544.

16. Vandamme D, et al. “A complete summary of LL-37, the factotum human cathelicidin peptide.” Cell Immunol. 2012;280(1):22-35.

17. Kovalzon VM, Strekalova TV. “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” J Neurochem. 2006;97(2):303-9.

18. Seredenin SB, et al. “Anxiolytic activity of the synthetic peptide selank.” Bull Exp Biol Med. 2006;142(3):356-8.

19. Dolotov OV, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Res. 2006;1117(1):54-60.

20. McCoy AT, et al. “Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.” J Pharmacol Exp Ther. 2013;344(1):141-54.

21. Dhillo WS, et al. “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.” J Clin Endocrinol Metab. 2005;90(12):6609-15.

22. Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015;21(3):443-54.

23. Hashimoto Y, et al. “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta.” Proc Natl Acad Sci USA. 2001;98(11):6336-41.